Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2025 After Market Close on February 25, 2026
Revolution Medicines (Nasdaq: RVMD) will report fourth quarter and full year 2025 financial results on Wednesday, February 25, 2026 after market close.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Revolution Medicines (Nasdaq: RVMD) will report fourth quarter and full year 2025 financial results on Wednesday, February 25, 2026 after market close. A senior management webcast will begin at 4:30 p.m. ET (1:30 p.m. PT) to discuss results and corporate progress. A replay will be available on the company website for at least 14 days.
Details
News Market Reaction – RVMD
On Feb 19, the first trading day after this news, RVMD closed 2.96% above the previous close.
Data tracked by StockTitan Argus for the Feb 19 session.
Key Figures
- Earnings report date
- February 25, 2026
- Fourth quarter and full year 2025 results release after market close
- Earnings call time ET
- 4:30 p.m. ET
- Start time for webcast to discuss Q4 and full-year results
- Earnings call time PT
- 1:30 p.m. PT
- Pacific Time for the same webcast event
- Webcast replay period
- 14 days
- Replay available on company website after the live webcast
Historical Context
-
Announcement of participation in Guggenheim biotech summit with webcast access.
-
First patient dosed in first-in-human trial for RMC-5127 RAS(ON) G12V inhibitor.
-
FDA Breakthrough Therapy Designation granted for zoldonrasib in NSCLC.
-
J.P. Morgan Healthcare Conference presentation with live and replay webcast.
-
First patient randomized in global Phase 3 RASolute 304 trial of daraxonrasib.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
REDWOOD CITY, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will report financial results for the fourth quarter and full year 2025 on Wednesday, February 25, 2026, after market close. At 4:30 p.m. ET that day (1:30 p.m. PT), members of Revolution Medicines’ senior management team will host a webcast to discuss the financial results for the quarter and full year, and provide an update on corporate progress.
To listen to the live webcast, or access the archived webcast, please visit: https://ir.revmed.com/events-and-presentations. Following the live webcast, a replay will be available on the company’s website for at least 14 days.
About Revolution Medicines, Inc.
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Additional development opportunities in the company’s pipeline focus on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C). For more information, please visit www.revmed.com and follow us on LinkedIn.
Revolution Medicines Media & Investor Contact:
media@revmed.com
investors@revmed.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.